Heron Therapeutics, Inc. - Common Stock (HRTX)

Heron (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics (NASDAQ:HRTX) said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter. Chief Executive Officer Craig Collard said the company entered 2026 w

Heron (HRTX) Q4 2025 Earnings Call Transcript

Heron Therapeutics reported mixed Q3 2025 results, missing revenue and earnings estimates. Despite strong growth from its Acute Care products, the miss led to a negative market reaction.

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

HRTX stock results show that Heron Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

HRTX stock results show that Heron Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.